Cognitive effects of pharmacotherapy for major depressive disorder: A systematic review

Richard S E Keefe, Shawn M. McClintock, Robert M. Roth, P. Murali Doraiswamy, Steven Tiger, Manisha Madhoo

Research output: Contribution to journalReview article

65 Citations (Scopus)

Abstract

Objective: Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission.This review examined pharmacotherapy effects on cognitive function in MDD. Data Sources: PubMed and EMBASE searches were conducted on July 30,2013, for English language reports of cognitive assessments following pharmacologic monotherapy or augmentation therapy in MDD. Study Selection: A total of 43 research reports were identified (31 monotherapy [8 placebo-controlled, 11 active-comparator, 12 open-label], 12 augmentation therapy [7 placebo-controlled, 5 open-label]). Data Extraction: Results reported in each publication were examined for open-label and placebo- or active comparator-controlled studies. Results: Studies varied widely in terms of size (median, 50 participants; interquartile range, 21-143 participants), populations examined, duration (median, 8 weeks; interquartile range, 6-12 weeks), and neurocognitive assessments used. Most individual studies reported some benefit to cognition with pharmacotherapy, but there was no pattern of response in specific domains and only 12% of individually analyzed changes favored active treatment over placebo or untreated healthy controls. Sample weighted mean effect sizes revealed that verbal memory improved with monotherapy, while the largest treatment effect with augmentation therapy was for visual memory. Conclusions: Pharmacotherapy may have benefit in reducing cognitive impairment in MDD, with augmentation therapy being a potential approach for addressing cognitive deficits that persist after monotherapy has brought about clinical response or remission. However, given the wide variability in study design and treatment duration across studies, these findings should be interpreted cautiously. More definitive research is required before firm conclusions can be reached.

Original languageEnglish (US)
Pages (from-to)864-876
Number of pages13
JournalJournal of Clinical Psychiatry
Volume75
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Major Depressive Disorder
Drug Therapy
Placebos
Cognition
Therapeutics
Information Storage and Retrieval
Systematic Review
Therapy
Pharmacotherapy
Augmentation
Placebo
PubMed
Publications
Language
Controlled
Remission
Cognitive Impairment
Research
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)
  • Medicine(all)

Cite this

Cognitive effects of pharmacotherapy for major depressive disorder : A systematic review. / Keefe, Richard S E; McClintock, Shawn M.; Roth, Robert M.; Murali Doraiswamy, P.; Tiger, Steven; Madhoo, Manisha.

In: Journal of Clinical Psychiatry, Vol. 75, No. 8, 01.01.2014, p. 864-876.

Research output: Contribution to journalReview article

Keefe, Richard S E ; McClintock, Shawn M. ; Roth, Robert M. ; Murali Doraiswamy, P. ; Tiger, Steven ; Madhoo, Manisha. / Cognitive effects of pharmacotherapy for major depressive disorder : A systematic review. In: Journal of Clinical Psychiatry. 2014 ; Vol. 75, No. 8. pp. 864-876.
@article{cdc270421d0446c79dd2db504752beb9,
title = "Cognitive effects of pharmacotherapy for major depressive disorder: A systematic review",
abstract = "Objective: Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission.This review examined pharmacotherapy effects on cognitive function in MDD. Data Sources: PubMed and EMBASE searches were conducted on July 30,2013, for English language reports of cognitive assessments following pharmacologic monotherapy or augmentation therapy in MDD. Study Selection: A total of 43 research reports were identified (31 monotherapy [8 placebo-controlled, 11 active-comparator, 12 open-label], 12 augmentation therapy [7 placebo-controlled, 5 open-label]). Data Extraction: Results reported in each publication were examined for open-label and placebo- or active comparator-controlled studies. Results: Studies varied widely in terms of size (median, 50 participants; interquartile range, 21-143 participants), populations examined, duration (median, 8 weeks; interquartile range, 6-12 weeks), and neurocognitive assessments used. Most individual studies reported some benefit to cognition with pharmacotherapy, but there was no pattern of response in specific domains and only 12{\%} of individually analyzed changes favored active treatment over placebo or untreated healthy controls. Sample weighted mean effect sizes revealed that verbal memory improved with monotherapy, while the largest treatment effect with augmentation therapy was for visual memory. Conclusions: Pharmacotherapy may have benefit in reducing cognitive impairment in MDD, with augmentation therapy being a potential approach for addressing cognitive deficits that persist after monotherapy has brought about clinical response or remission. However, given the wide variability in study design and treatment duration across studies, these findings should be interpreted cautiously. More definitive research is required before firm conclusions can be reached.",
author = "Keefe, {Richard S E} and McClintock, {Shawn M.} and Roth, {Robert M.} and {Murali Doraiswamy}, P. and Steven Tiger and Manisha Madhoo",
year = "2014",
month = "1",
day = "1",
doi = "10.4088/JCP.13r08609",
language = "English (US)",
volume = "75",
pages = "864--876",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Cognitive effects of pharmacotherapy for major depressive disorder

T2 - A systematic review

AU - Keefe, Richard S E

AU - McClintock, Shawn M.

AU - Roth, Robert M.

AU - Murali Doraiswamy, P.

AU - Tiger, Steven

AU - Madhoo, Manisha

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission.This review examined pharmacotherapy effects on cognitive function in MDD. Data Sources: PubMed and EMBASE searches were conducted on July 30,2013, for English language reports of cognitive assessments following pharmacologic monotherapy or augmentation therapy in MDD. Study Selection: A total of 43 research reports were identified (31 monotherapy [8 placebo-controlled, 11 active-comparator, 12 open-label], 12 augmentation therapy [7 placebo-controlled, 5 open-label]). Data Extraction: Results reported in each publication were examined for open-label and placebo- or active comparator-controlled studies. Results: Studies varied widely in terms of size (median, 50 participants; interquartile range, 21-143 participants), populations examined, duration (median, 8 weeks; interquartile range, 6-12 weeks), and neurocognitive assessments used. Most individual studies reported some benefit to cognition with pharmacotherapy, but there was no pattern of response in specific domains and only 12% of individually analyzed changes favored active treatment over placebo or untreated healthy controls. Sample weighted mean effect sizes revealed that verbal memory improved with monotherapy, while the largest treatment effect with augmentation therapy was for visual memory. Conclusions: Pharmacotherapy may have benefit in reducing cognitive impairment in MDD, with augmentation therapy being a potential approach for addressing cognitive deficits that persist after monotherapy has brought about clinical response or remission. However, given the wide variability in study design and treatment duration across studies, these findings should be interpreted cautiously. More definitive research is required before firm conclusions can be reached.

AB - Objective: Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission.This review examined pharmacotherapy effects on cognitive function in MDD. Data Sources: PubMed and EMBASE searches were conducted on July 30,2013, for English language reports of cognitive assessments following pharmacologic monotherapy or augmentation therapy in MDD. Study Selection: A total of 43 research reports were identified (31 monotherapy [8 placebo-controlled, 11 active-comparator, 12 open-label], 12 augmentation therapy [7 placebo-controlled, 5 open-label]). Data Extraction: Results reported in each publication were examined for open-label and placebo- or active comparator-controlled studies. Results: Studies varied widely in terms of size (median, 50 participants; interquartile range, 21-143 participants), populations examined, duration (median, 8 weeks; interquartile range, 6-12 weeks), and neurocognitive assessments used. Most individual studies reported some benefit to cognition with pharmacotherapy, but there was no pattern of response in specific domains and only 12% of individually analyzed changes favored active treatment over placebo or untreated healthy controls. Sample weighted mean effect sizes revealed that verbal memory improved with monotherapy, while the largest treatment effect with augmentation therapy was for visual memory. Conclusions: Pharmacotherapy may have benefit in reducing cognitive impairment in MDD, with augmentation therapy being a potential approach for addressing cognitive deficits that persist after monotherapy has brought about clinical response or remission. However, given the wide variability in study design and treatment duration across studies, these findings should be interpreted cautiously. More definitive research is required before firm conclusions can be reached.

UR - http://www.scopus.com/inward/record.url?scp=84908350036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908350036&partnerID=8YFLogxK

U2 - 10.4088/JCP.13r08609

DO - 10.4088/JCP.13r08609

M3 - Review article

C2 - 25099527

AN - SCOPUS:84908350036

VL - 75

SP - 864

EP - 876

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -